1. 1. Huang RF, Shao WB. The report on accessibility of rare diseases drugs in China, 2019. China Organization for Rare Disorders, IQVIA. 2019; pp.1-20. (in Chinese)
2. 2. Ding JX, Ji N, Bai GL. Study of orphan drug market protection policy in China. Chinese Journal of Pharmaceuticals. 2012; 43:959-965. (in Chinese)
3. 3. Gong SW, Xu Y, Zhang L. Study on evaluation indicator system of drug accessibility. Chinese Health Economics. 2011; 30:72-74. (in Chinese)
4. 4. Ding J, Wang L. Chinese rare disease research report (2018). China Medical Science Press, Beijing, China, 2018; pp.1-22. (in Chinese)
5. 5. The State Council. The Notice of the State Council on National Drug Safety During the 12th Five-Year Plan. http://www.gov.cn/zwgk/2012-02/13/content_2065197. htm (accessedApril 5 , 2019). (in Chinese)